Data from pivotal international phase III clinical trials showed superior efficacy, safety, and convenience for a new wave of direct-acting oral agents. The breakthrough will benefit physicians in all practice settings, including primary care.
A presentation on October 14, 2013, at the American College of Gastroenterology Scientific Session by Joseph A. Murray, MD, FACG (Mayo Clinic)Murray JA. Implications of gluten intolerance and celiac disease in IBS.
What accounts for the 129% increase in admissions for constipation over the past decade—and what can be done to avoid these expensive and often unnecessary admissions? Primary care clinicians take note.